Study: Biosimilars Market to Grow by 56.7% by 2017

A new report finds that the market earned revenue of around US$172m in 2010 and estimates that this will reach nearly $4bn by 2017 at a compound annual growth rate of 56.7% from 2010 to 2017.

According to a new report from Frost & Sullivan, impending patent expiries of blockbuster drugs are expected to result in the introduction of several new biosimilars and boost market development.

The Analysis of European Biosimilars Market report finds that the market earned revenue of around US$172m in 2010 and estimates that this will reach nearly $4bn by 2017 at a compound annual growth rate (CAGR) of 56.7% from 2010 to 2017.

The study covers existing biosimilars segments (erythropoietin, granulocyte colony stimulating factors and human growth hormones) and the emerging segment that includes monoclonal antibodies, insulin and alpha and beta interferon.

"The expiration of patents and other intellectual